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Background.– Botulinum toxin type A (BoNT-A) injections are a key treatment
in the interdisciplinary management of patients with spasticity. Here, we present
interim analyses of characteristics of physicians participating in the SPACE
study.
Methods.– SPACE, an international, observational study of the safety and effec-
tiveness of several BoNT-As, followed previously BoNT-naïve patients with
spasticity for up to 2 years. Data regarding physicians’ speciality, medical expe-
rience, BoNT-A dosing preferences and treatment approaches were collected.
Results.– These interim analyses included 230 physicians* from Europe (66.1%),
Canada (6.1%), Mexico (4.8%) and Russia (5.7%). Most physicians were neu-
rologists (50.9%) or physiatrists (36.5%). Treating physicians had a median
15 years’ experience in medical practice (range 1–36 years; experience with
BoNT-A, 0–25 years [median 8.5 years]). Most physicians (60.9%) would inject
higher BoNT-A doses if permitted by product labelling. For 48.9% of patients
(317/648)*, the BoNT-A treatment decision was agreed by a multidisciplinary
team.
*Interim analyses – data were not yet available for all physicians/patients.
Conclusions.– Data from the SPACE study will further improve our understan-
ding of physician practice with BoNT-A for treating patients with spasticity
in a routine setting, identify challenges in managing these patients and aid
optimisation of treatment approaches.
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Background.– Botulinum toxin A (BoNT-A) injections are a key treatment for
patients with spasticity. Here, we present interim analyses of patient baseline
characteristics in SPACE, an international, non-interventional study of the safety
and effectiveness of BoNT-A formulations.
Methods.– SPACE followed BoNT treatment-naïve patients with spasticity (any
aetiology) for up to 2 years. Data collected included baseline disease characte-
ristics and key treatment goals, as agreed by each patient and physician.
Results.– These interim analyses include 648 patients* (61.9% male, mean
[standard deviation (SD)] age 54.8 [15.6] years). Causes of spasticity inclu-
ded stroke (66.4%), multiple sclerosis (9.7%) and brain injury (6.5%). Most
patients (79.3%) were hemiplegic (diplegic, 11.7%; quadriplegic, 7.9%). Median
time since the spasticity-causing event was 2.0 years (range 0–63 years). Many
patients (57.4%) reported spasticity-related pain (mild, 20.1%; moderate, 28.1%;
severe, 9.3%). The most common key treatment goals were “improvement in
mobility” (20.5%), “improvement in dexterity and reaching” (15.7%) and “pain
relief” (11.9%).
*Interim analyses – data were not yet available for all patients.
Conclusions.– Data from SPACE will help to further define the role of BoNT-
A as part of a multimodal management approach for focal spasticity and aid
patients in this diverse population achieve individual treatment goals.
http://dx.doi.org/10.1016/j.rehab.2014.03.168
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Background.– In adult, stroke patients maximal recommended dose of onabo-
tulinumtoxinA is 600 UI, with reported generalised side-effects at 800 UI [1].
Doses up to 840 UI of IncobotulinumtoxinA have been reported in a case without
side effects, but more precise data are lacking [2]. We report the use of high doses
of incobotulinumtoxinA in a group of patients.
Methods.– Clinical records of 46 stroke survivors (19 females) with spastic
hemiplegia treated with IncobotulinumtoxinA (100 UI:2 mL of 0.9% NaCl), with
doses ≥ 500 UI (maximal dose < 14 UI/Kg) were reviewed. Muscles, dose for
each muscle, Ashworth grade before and 1 month after treatment and side effects
were recorded.
Results.– Mean incobotulinumtoxinA dose was 638.3 ± 106.9 UI. Mean Ash-
worth score at injected muscle was 3.39 ± 0.94 (median 3, IQR 3–5) before
treatment and 1.22 ± 1.04 (median 1, IQR 0–5) after treatment. Twenty-three
patients had ≥ 700 UI. Each patient had a mean of 9.65 muscles treated. No
adverse events were noted in this group.
Conclusions.– In our retrospective analysis, incobotulinumtoxinA at high doses
in multifocal treatment for spasticity showed to be effective and safe.
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Background.– In rodents, botulinum toxin type A (BoNT-A) is retrogradely
transported to second-order neurons in the central nervous system (CNS). At
present, time data in humans are missing.
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HRV has been widely used to evaluate the control exerted by the autonomic
nervous system on cardiovascular activities, including vagal and sympathetic
components.
The aim of this study was to evaluate changes in HRV induced by BoNT-A
(NT-201) injection in spastic stroke patients.
Methods.– Eleven stroke survivors with spastic hemiplegia were injected with
IncobotulinumtoxinA (100 units:2 mL of 0.9% NaCl), with doses ≥ 600 UI
(maximal dose < 12 UI/Kg). They received two ECG registrations of 30 min
each, the first 24 h before injection and the second 10 days after.
Linear and non-linear HRV variables were obtained with HRV analysis
software.
Results.– None of the variable considered for time, frequency domain and non-
linear domain suffer significant changes after BoNT-A injection.
Conclusions.– High doses of BoNT-A do not influence cardiac autonomic drive.
Moreover, no clinical adverse events of any kind occurred in anyone of our
patients after NT-201 injection.
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Background.– Previous results in patients injected with abobotulinum toxin
A and onabotulinum toxin A have shown that injection intervals shorter than
2 months may increase the risk for neutralising antibody formation and treat-
ment non-response. As a result, for the last 10 years, we have adopted longer
intervals to treat patients with spasticity and/or dystonia secondary to stroke.
It has been showed that incobotulinum toxin A does not induce neutralising
antibodies.
Observations.–
Methods.– Ten patients with spasticity and/or dystonia due to stroke underwent
a booster injection one month after the first injection. The clinical results were
compared to those previously obtained in the same 10 patients using a single
injection. Secondary dystonia was evaluated using the Unified Dystonia Rating
Scale (UDRS), while spasticity was evaluated according to the Modified Ash-
worth Scale (MAS).
Results.– They showed that the booster injection protocol induced an improve-
ment in 8 subjects. In the remaining 2 subjects, we did not find any difference
between the results obtained using the single and the booster injection protocols.
Conclusions.– The use of a booster injection improve the clinical out-
come in patients with spasticity and/or dystonia after stroke, allowing
an optimal treatment of those muscles that poorly responded to the first
injection.
http://dx.doi.org/10.1016/j.rehab.2014.03.171
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Background.– SPACE, an international, non-interventional study, is collecting
effectiveness, safety and quality of life (QoL) data on botulinum toxin type A
(BoNT-A) treatment for spasticity in a routine practice setting. Here, we present
interim analyses of the first treatment cycle.
Methods.– BoNT treatment-naïve adults with spasticity of any aetiology were
followed for up to 2 years. Data collected include global assessments of efficacy
(patient-rated [PGAE] and investigator-rated [IGAE]) and investigator global
assessment of tolerability (IGAT). Global assessments were made at the end of
the first treatment cycle and scored from 1 = very good to 4 = poor. PGAE/IGAE
responders were defined as patients with scores ≤ 3 = moderate.
Results.– The interim analyses include 648 patients* (61.9% male, mean [stan-
dard deviation] age 54.8 [15.6] years) who received 1 treatment cycle with
incobotulinumtoxinA (n = 435), onabotulinumtoxinA (n = 138) or abobotuli-
numtoxinA (n = 75). Overall, 468/510 (91.8%) patients were PGAE responders
and 476/500 (95.2%) patients were IGAE responders. IGAT was very good or
good for 467/500 (93.4%) patients.
*Interim analyses – data were not yet available for all patients
Conclusions.– For patients with focal spasticity, their first-ever BoNT-A treat-
ment cycle was efficacious and well tolerated. Longer-term data will assess the
benefits of BoNT-A injections over multiple treatment cycles.
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Background.– Previous studies have shown the efficacy of botulinum toxin type
A (BoNT-A) in the management of ambulant individuals with cerebral palsy
(CP). We evaluated the efficacy of incobotulinum toxin A (Xeomin®) injections
in children with dynamic equinus affected by hemiplegic CP in polycentric study.
Methods.– The efficacy of treatment was tested in 30 children aged from 2 to
18 years with spasticity more than 2 at Modified Ashworth Scale, injections were
performed in calf muscles up to 200 U, with electromyographic guidance. The
treatment efficacy was evaluated with the Modified Ashworth Scale, Tardieu
Scale, Active and Passive Range of motion and Walking test on 10 m. Clinical
data were collected at time 0 and at 1, 3 and 6 months after the injections.
Results.– Preliminary data showed good efficacy and tolerability of treatment
spasticity with botulinum toxin A in children.
Conclusions.– Incobotulinum toxin A seems to be as effective as other type A
botulinum toxins. The absence of proteins could be an advantage in the paediatric
population requiring repeated treatments over time.
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